MKMark H. Kuniholm

Mark H. Kuniholm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark H. Kuniholm has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Human leucocyte antigen class I and II imputation in a multiracial population

    by M. H. Kuniholm, X. Xie, K. Anastos, X. Xue, L. Reimers, A. L. French, S. J. Gange, S. G. Kassaye, A. Kovacs, T. Wang, et al.

    Summary: Human leucocyte antigen (HLA) genes play a central role in response to pathogens and in autoimmunity. Research to understand the effects of HLA genes on health has been limited because HLA genotyping protocols are labour intensive and expensive. Recently, algorithms to impute HLA genotype data using genome‐wide association study (GWAS) data have been published. However, imputation accuracy for most of these algorithms was based primarily on training data sets of European ancestry individuals. We considered performance of two HLA‐dedicated imputation algorithms – SNP2HLA and HIBAG – in a multiracial population of n = 1587 women with HLA genotyping data by gold standard methods. We first compared accuracy – defined as the percentage of correctly predicted alleles – of HLA‐B and HLA‐C imputation using SNP2HLA and HIBAG using a breakdown of the data set into an 80% training group and a 20% testing group. Estimates of accuracy for HIBAG were either the same or better than those for SNP2HLA. We then conducted a more thorough test of HIBAG imputation accuracy using five independent 10‐fold cross‐validation procedures with delineation of ancestry groups using ancestry informative markers. Overall accuracy for HIBAG was 89%. Accuracy by HLA gene was 93% for HLA‐A, 84% for HLA‐B, 94% for HLA‐C, 83% for HLA‐DQA1, 91% for HLA‐DQB1 and 88% for HLA‐DRB1. Accuracy was highest in the African ancestry group (the largest group) and lowest in the Hispanic group (the smallest group). Despite suboptimal imputation accuracy for some HLA gene/ancestry group combinations, the HIBAG algorithm has the advantage of providing posterior estimates of accuracy which enable the investigator to analyse subsets of the population with high predicted (e.g. >95%) imputation accuracy.


  • Open Access

    Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women

    by Mark H. Kuniholm, Thomas R. O'BRien, Ludmila Prokunina-Olsson, Michael Augenbraun, Michael Plankey, Roksana Karim, Monika Sarkar, Audrey L. French, Chris Pierce, Howard D. Strickler, et al.

    Recent studies reported that the CD4/CD8 T-cell ratio is inversely associated with biomarkers traditionally used to measure immune activation and systemic inflammation in highly active antiretroviral therapy–treated HIV-infected (HIV+) patients. The relation of hepatitis C virus (HCV) coinfection with the CD4/CD8 ratio in HIV+ patients is unknown. We examined 50,201 CD4/CD8 ratios measured over 20 years in 3 groups of HIV+ women enrolled in the Women's Interagency HIV Study: HCV antibody negative (n = 1734), cleared HCV (n = 231), and chronic HCV (n = 751) in multivariate models. IFNL4-ΔG genotype and HCV viral load were also considered. Compared with HCV antibody negative status, chronic HCV infection was associated with lower CD4/CD8 ratios when HIV viral load was suppressed to the lower limit of quantification (β = −0.08; P = 0.002). Cleared HCV (β = −0.10; P = 0.0009), but not IFNL4-ΔG genotype or HCV viral load, was also associated with lower CD4/CD8 ratios when HIV viral load was suppressed to the lower limit of quantification. The association of HCV coinfection with CD4/CD8 ratio is consistent with previously observed associations of HCV coinfection with biomarkers traditionally used to measure immune activation and systemic inflammation in HIV+ patients. These data provide additional support for the use of CD4/CD8 ratio for routine monitoring of immune activation and inflammation in HIV+ patients, including those with HIV/HCV coinfection; however, the unexpected association between cleared HCV and lower CD4/CD8 ratio requires additional study.


  • Awareness of Hepatitis C Virus Seropositivity and Chronic Infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

    by Mark H. Kuniholm, Molly Jung, Julia Del Amo, Gregory A. Talavera, Bharat Thyagarajan, Ronald C. Hershow, Oriana M. Damas, Robert C. Kaplan

    Few population-based studies have assessed awareness of hepatitis C virus (HCV) seropositivity and chronic infection. We report awareness of HCV seropositivity and chronic infection and correlates of awareness in a multi-city (Bronx, Miami, Chicago, and San Diego) community-dwelling population sample of United States (US) Hispanics/Latinos recruited during 2008–2011. Included were 260 HCV-seropositive participants, among whom 190 had chronic HCV. Among those with chronic HCV, 46 % had been told by a doctor that they had liver disease and 32 % had been told that they had HCV-related liver disease. Among those with chronic HCV who also lacked health insurance (37 % of those with chronic HCV), only 8 % had been told that they had HCV-related liver disease. As compared with the uninsured, those with insurance were over five times more likely to be aware of having HCV-related liver disease (44 %). Sex, age, education, city of residence, and birthplace were not associated with HCV awareness. Less than half of Hispanics/Latinos were aware of their HCV chronic infection. Lack of health insurance may be an important barrier to HCV awareness in this population.


  • Open Access

    Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus‐Infected U.S. Women

    by Mark H. Kuniholm, Edgar Ong, Boris M. Hogema, Marco Koppelman, Kathryn Anastos, Marion G. Peters, Eric C. Seaberg, Yue Chen, Kenrad E. Nelson, Jeffrey M. Linnen

    Exposure to hepatitis E virus (HEV) is common in the United States, but there are few data on prevalence of HEV/human immunodeficiency virus (HIV) coinfection in U.S. populations. We tested 2,919 plasma samples collected from HIV‐infected (HIV+) women and men enrolled in U.S. cohort studies for HEV viremia using a high‐throughput nucleic acid testing (NAT) platform. NAT+ samples were confirmed by real‐time polymerase chain reaction. Samples were selected for testing primarily on the basis of biomarkers of liver disease and immune suppression. Prevalence of HEV viremia was 3 of 2,606 and 0 of 313 in tested plasma samples collected from HIV+ women and men, respectively. All HEV isolates were genotype 3a. Based on follow‐up testing of stored samples, 1 woman had chronic HEV infection for >4 years whereas 2 women had acute HEV detectable at only a single study visit. Conclusions: To our knowledge, this is the first reported case of chronic HEV infection in an HIV+ U.S. individual. We also confirm that chronic HEV infection can persist despite a CD4+ count >200 cells/mm3. Overall, though, these data suggest that HEV infection is rare in the HIV+ U.S. population. (Hepatology 2016;63:712–720)


  • Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers

    by Mark H. Kuniholm, Terry Leach, Joseph Lunievicz, Noemí Olivo, Kathryn Anastos, Yvette Vazquez, Mark Brennan-Ing, Stephen E. Karpiak, Oladipo Alao, Denis Nash, et al.


  • Open Access

    The distribution of hepatitis B virus exposure and infection in a population‐based sample of U.S. Hispanic adults

    by Molly Jung, Mark H. Kuniholm, Gloria Y.F. Ho, Scott Cotler, Howard D. Strickler, Bharat Thyagarajan, Marston Youngblood, Robert C. Kaplan, Julia del Amo

    Little is known regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Latinos. We sought to determine the prevalence of HBV exposure (serum HBV core antibody; anti‐HBc), active HBV infection (serum HBV surface antigen; HBsAg), and vaccine‐induced HBV immunity (antibody against HBV surface antigen; anti‐HBs) in U.S. Hispanics/Latinos and consider how these data inform clinical screening recommendations. Our analysis included 11,999 women and men of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a population‐based, household survey in four urban communities (Bronx, NY; Miami, FL; Chicago, IL; and San Diego, CA) of U.S. civilian, noninstitutionalized self‐identifying Hispanic/Latino adults ages 18‐74. Vaccine‐induced immunity was defined as detection of anti‐HBs, but not anti‐HBc. However, if anti‐HBc were present, it was considered evidence of exposure to HBV, with detection of HBsAg used to distinguish those with active HBV infection. Mean age was 45.7 years, and 7,153 were women. Vaccine‐induced immunity was greatest among those ages 18‐29 years (60.2% in women, 54% in men) and decreased with increasing age, regardless of country of birth. The prevalence of active HBV infection was 0.29% (95% confidence interval: 0.19‐0.43), but varied by country of birth. Those born in the Dominican Republic had the highest prevalence of HBV exposure (20.3% in women, 29.7% in men) and active HBV infection (0.95%). Conclusions: The overall age‐standardized prevalence of active HBV infection in Hispanic/Latino adults (0.29%) was no different from the general U.S. population estimate (0.27%) and did not exceed 2%, regardless of country of birth. These data do not support targeting HBV screening to US Hispanic/Latino adults based upon background. (Hepatology 2016;63:445–452)


  • Association of Chronic Hepatitis C Infection With T-Cell Phenotypes in HIV-Negative and HIV-Positive Women

    by Mark H. Kuniholm, Xianhong Xie, Kathryn Anastos, Robert C. Kaplan, Xiaonan Xue, Andrea Kovacs, Marion G. Peters, Eric C. Seaberg, Audrey L. French, Mary A. Young, et al.

    Background: Hepatitis C virus (HCV) viremia is thought to have broad systemic effects on the cellular immune system that go beyond its impact on just those T cells that are HCV specific. However, previous studies of chronic HCV and circulating T-cell subsets (activation and differentiation phenotypes) in HIV negatives used general population controls, rather than a risk-appropriate comparison group. Studies in HIV positives did not address overall immune status (total CD4+ count). Methods: We used fresh blood from HIV-positive and at-risk HIV-negative women, with and without chronic HCV, to measure percentages of activated CD4+ and CD8+ T cells, Tregs, and T-cell differentiation phenotypes (naive, central memory, effector memory (EM), and terminally differentiated effector). This included 158 HIV negatives and 464 HIV positives, of whom 18 and 63, respectively, were HCV viremic. Results: In multivariate models of HIV negatives, HCV viremia was associated with 25% fewer naive CD4+ (P = 0.03), 33% more EM CD4+ (P = 0.0002), and 37% fewer central memory CD8+ (P = 0.02) T cells. Among HIV positives, we observed only 1 of these 3 relationships: higher percentage of EM CD4+ among HCV viremic women. Furthermore, the association with EM CD4+ among HIV positives was limited to individuals with diminished immune status (total CD4+ count ≤500 cells/μL), as were associations of HCV viremia with higher percentages of activated CD4+ and Tregs. Among HIV positives with high CD4+ count, no significant associations were observed. Conclusions: These data suggest that HCV viremia in HIV negatives is associated with accelerated T-cell differentiation, but among HIV positives, the impact of HCV viremia is less straightforward and varies by total CD4+ count.


  • Open Access

    Hepatitis E virus seroprevalence in the United States: No easy answers

    by Mark H. Kuniholm, Ronald E. Engle, Robert H. Purcell, Kenrad E. Nelson


  • Open Access

    Prevalence of Hepatitis C Virus Infection in US Hispanic/Latino Adults: Results From the NHANES 2007–2010 and HCHS/SOL Studies

    by Mark H. Kuniholm, Molly Jung, James E. Everhart, Scott Cotler, Gerardo Heiss, Geraldine McQuillan, Ryung S. Kim, Howard D. Strickler, Bharat Thyagarajan, Marston Youngblood, et al.

    Prevalence of hepatitis C virus (HCV) antibody has been reported in Mexican Americans, but its prevalence in other US Hispanic/Latino groups is unknown. We studied 2 populations of US Hispanic/Latino adults; 3210 from the National Health and Nutrition Examination Survey (NHANES) 2007–2010 and 11 964 from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Age-standardized prevalence of HCV antibody was similar in NHANES 2007–2010 (1.5%) and HCHS/SOL (2.0%) but differed significantly by Hispanic/Latino background in HCHS/SOL (eg, 11.6% in Puerto Rican men vs 0.4% in South American men). These findings suggest that the HCV epidemic among US Hispanics/Latinos is heterogeneous.